# 🤰 Pregnancy & Special Populations

## ⚠️ Critical Safety Alert

**30-60 minute window** for treating severe hypertension (≥160/110 mmHg) represents a critical patient safety metric. Delayed treatment associated with maternal stroke.

### 🔬 CHAP Trial Revolutionary Evidence

#### 🎯 Trial Design

- **Population:** 2,408 pregnant women with mild chronic HTN
- **BP Range:** 140-159/85-89 mmHg
- **Intervention:** Active treatment vs standard care
- **Primary Outcome:** Composite pregnancy complications

#### 📊 Key Results

- **approximately 18% relative reduction** in composite adverse outcomes (rate 30.2% vs 37.0%, adjusted RR 0.82; ARR approximately 6.8%)
- **No increase** in fetal growth restriction
- **Class 1 recommendation** for treatment ≥140/90 mmHg
- **Source:** Tita AT et al. *NEJM* 2022;386(19):1781-1792, PMID 35363951

### 🎯 2025 Treatment Thresholds

#### ✅ Chronic Hypertension

**Treatment Threshold:** ≥140/90 mmHg

**Target:** 120-160/80-105 mmHg

**Evidence:** CHAP trial Class 1 recommendation

**Benefit:** approximately 18% relative reduction in adverse outcomes (HR 0.82; ARR approximately 6.8%; rate 30.2% vs 37.0%)

#### 🚨 Severe Hypertension

**Definition:** ≥160/110 mmHg

**Action Timeline:** 30-60 minutes

**Target:** 140-150/90-100 mmHg

**Risk:** Maternal stroke if delayed

### 💊 Pregnancy Medication Safety Profile

#### ✅ SAFE - First Line

##### Labetalol

**Dose:** 100-400 mg BID

**Avoid:** Asthma, heart block

**Benefits:** Both α/β blockade

##### Extended-Release Nifedipine

**Dose:** 30-120 mg daily

**Monitor:** Tocolytic effects near term

**Benefits:** Effective, well-tolerated

#### ⚠️ CAUTION - Second Line

##### Methyldopa

**Dose:** 250-1000 mg BID-TID

**Issues:** Less effective, sedation

**Historical:** Longest safety data

##### Hydralazine

**Use:** Acute severe HTN only

**Route:** IV/IM for emergencies

**Risk:** Unpredictable hypotension

#### ❌ CONTRAINDICATED

##### ACE Inhibitors

**Risk:** Oligohydramnios, renal dysgenesis

**Timing:** Teratogenic 2nd/3rd trimester

##### ARBs & Atenolol

**ARBs:** Similar teratogenic risk as ACEIs

**Atenolol:** IUGR associations

##### MRA & Direct Renin Inhibitors

**Risk:** Teratogenic potential

**Avoid:** All pregnancy stages

### 🚨 Severe Hypertension Emergency Protocol

**BP ≥160/110 mmHg → Action within 30-60 minutes**

#### 1️⃣ Assess

Confirm BP elevation, symptoms, target organ damage

#### 2️⃣ Laboratory

CBC, CMP, LFTs, uric acid, 24h urine or protein/creatinine

#### 3️⃣ First-Line

Labetalol 20mg IV → 40mg → 80mg Q20min (max 300mg)

#### 4️⃣ Alternative

Hydralazine 5-10mg IV Q20-40min (max 30mg) or Nicardipine gtt

#### 5️⃣ Target

140-150/90-100 mmHg (avoid \<140 mmHg)

#### 6️⃣ Monitor

Continuous fetal monitoring, maternal neurologic status

### 🧮 Pregnancy Hypertension Risk Calculator

Maternal Age Pre-pregnancy BP Category Additional Risk Factors Diabetes/Gestational DM Obesity (BMI \>30) Previous Preeclampsia Chronic Kidney Disease Gestational Age (weeks)

#### 

### 🏥 Postpartum Management (Extended to 12 Weeks)

0-72 hours **Immediate monitoring:** BP every 4-6 hours, watch for delayed preeclampsia. Continue antihypertensive medications. Monitor for postpartum hemorrhage and fluid shifts. 3-7 days **Transition planning:** Adjust medications for breastfeeding compatibility. Daily BP checks. Assess for headache, visual changes, or epigastric pain. 1-2 weeks **First follow-up:** BP reassessment, medication adjustment. Screen for postpartum depression. Evaluate breastfeeding success. 6-12 weeks **Long-term planning:** Cardiovascular risk stratification using PREVENT calculator. Transition to standard antihypertensive regimen. Family planning counseling.

### 🤱 Breastfeeding Medication Compatibility

#### ✅ Compatible

- **Labetalol:** Minimal milk transfer
- **Nifedipine:** Low milk concentration
- **Enalapril:** Preferred ACE inhibitor
- **Captopril:** Alternative ACE inhibitor

#### ⚠️ Use with Caution

- **Methyldopa:** Monitor infant drowsiness
- **Propranolol:** Monitor infant HR, hypoglycemia
- **Hydrochlorothiazide:** May reduce milk supply

#### ❌ Avoid if Possible

- **Atenolol:** High milk concentration
- **Reserpine:** Nasal congestion, lethargy
- **High-dose diuretics:** Milk supply reduction

### 👥 Special Population Considerations

#### 🧓 Elderly (≥65 years)

- Target: \<140/90 mmHg initially, then \<130/80 if tolerated
- Avoid: Orthostatic hypotension, cognitive impairment
- Monitor: Falls risk, polypharmacy interactions
- Prefer: Low-dose combination therapy

#### 🏃‍♀️ Athletes & Young Adults

- Rule out: Secondary causes, white-coat HTN
- Screening: Echo for LVH, exercise stress test
- Avoid: Beta-blockers in competitive athletes
- Target: \<130/80 mmHg for long-term CV protection

#### 🧬 Genetic Considerations

- African ancestry: Enhanced response to CCBs, diuretics
- Asian ancestry: Lower renin, increased salt-sensitivity
- Pharmacogenomics: CYP2D6 variants affect metoprolol
- Family history: Early screening, intensive targets

## 📚 Sources

1.  **Tita AT, Szychowski JM, Boggess K, et al; CHAP Trial Consortium.** Treatment for Mild Chronic Hypertension during Pregnancy. *N Engl J Med.* 2022;386(19):1781-1792. [PMID: 35363951](https://pubmed.ncbi.nlm.nih.gov/35363951/). \[Source for: CHAP composite adverse outcome 30.2% vs 37.0% (adjusted RR 0.82, ARR approximately 6.8%); N=2,408. Established Class 1 treatment threshold ≥140/90 mmHg in chronic HTN of pregnancy.\]
2.  **Magee LA, von Dadelszen P, Rey E, et al.** Less-tight versus tight control of hypertension in pregnancy: CHIPS. *N Engl J Med.* 2015;372(5):407-417. [PMID: 25629739](https://pubmed.ncbi.nlm.nih.gov/25629739/). \[Source for: less-tight (DBP target 100) vs tight (DBP target 85) — primary composite no difference, but tight control reduced severe HTN; pre-CHAP foundational evidence.\]
3.  **Koopmans CM, Bijlenga D, Groen H, et al; HYPITAT study group.** Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks: HYPITAT. *Lancet.* 2009;374(9694):979-988. [PMID: 19656558](https://pubmed.ncbi.nlm.nih.gov/19656558/). \[Source for: induction at ≥36 weeks reduces severe maternal morbidity in gestational HTN / mild preeclampsia; informs delivery timing recommendations.\]
4.  **ACOG Committee on Practice Bulletins—Obstetrics.** Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Number 222. *Obstet Gynecol.* 2020;135(6):e237-e260. [PMID: 32443079](https://pubmed.ncbi.nlm.nih.gov/32443079/). \[Source for: ACOG severe HTN definition ≥160/110, 30-60 minute window for IV therapy, magnesium sulfate for preeclampsia with severe features.\]
5.  **Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC.** Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. *BMJ.* 2014;348:g2301. [PMID: 24735917](https://pubmed.ncbi.nlm.nih.gov/24735917/). \[Source for: baseline maternal and fetal risks in chronic HTN of pregnancy — superimposed preeclampsia rate, IUGR rate, perinatal mortality.\]

### 🎯 Key Learning Points

#### 🔬 Evidence-Based Practice

- CHAP trial supports treating mild chronic HTN in pregnancy
- approximately 18% relative reduction in adverse outcomes (HR 0.82; ARR approximately 6.8%; rate 30.2% vs 37.0%) without fetal harm
- Class 1 recommendation for treatment ≥140/90 mmHg

#### ⏰ Critical Timelines

- 30-60 minutes for severe HTN (≥160/110 mmHg)
- Extended postpartum monitoring through 12 weeks
- Delayed preeclampsia recognition and management

#### 💊 Safe Medication Choices

- Labetalol and extended-release nifedipine preferred
- Absolute contraindication of ACE/ARB/MRA
- Breastfeeding compatibility considerations

#### 👥 Population-Specific Care

- Individualized targets based on age and comorbidities
- Genetic ancestry influences drug response
- Special considerations for athletes and elderly


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/pregnancy-special-populations.html) · Markdown synchronized October 3, 2026.